By December 2024, nearly 20 Chinese startups had become members of the Roche Accelerator initiative in China, working in a wide range of areas including novel biological mechanisms, platforms and drug modalities, molecular glues (small molecules that facilitate protein interactions), cyclic peptides, novel drug conjugates and RNA and cell therapies.
Roche Accelerator Deepens Pool Of Potential Chinese Partners
Roche's Shanghai-based Accelerator now includes close to 20 Chinese startups across multiple areas including novel modalities and AI-based research, fitting into the Swiss major's strategy of partnering in core areas to access innovation.
